Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.
Pharnext SA announced its financial results for the fiscal year ended December 31st, 2018.
MDxHealth SA, a commercial-stage innovative molecular diagnostics company, provided a business update for the first quarter ended March 31, 2019.
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.
Eur 140 m bridge loan was drawn to secure evotec’s value chain expansion by successful acquisition of aptuit in august 2017
312 shareholders attended, representing 60% of the issued share capital
All investments in healthcare businesses progressing as planned to further accelerate growth
Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT
The report summarises the business and highlights for 2018 and gives insights into the company’s strategy.